All For One Steeb AG (A1OS)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 76.20 |
|---|---|
| 52-week range | 27.30 – 77.00 |
| Return, 1 month / 3 months | +7.0% / +13.1% |
| Return, 1 year / 3 years | +90.5% / +117.9% |
| Trend | Uptrend |
| RSI (14) | 86 |
| Volatility (1 year) | 83.5% |
| Worst drawdown (1 year) | -29.9% |
| Average daily value traded | 0.33M EUR |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
All For One Steeb AG is a German information technology services company that concentrates on SAP software. It advises, implements and operates SAP systems for mid-sized businesses and public-sector organisations, and it also offers related services such as cloud hosting, application management and support. The company is based in Filderstadt, near Stuttgart, and serves customers mainly in German-speaking markets, helping them run and modernise their business software.
On this site All For One Steeb AG appears as a stock on the XETRA Stock Exchange (Germany), code A1OS, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
All For One Steeb AG (A1OS) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 76.20 on 22 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 132 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 90.5% and over the last three months it rose 13.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 99 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 62.5% | ||
| From 52-week high | 0.0% | ||
| Momentum | 92 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 13.1% | ||
| 6-month return | 107.1% | ||
| 12-month return, skipping the last month | 78.0% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 83.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.9% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.33M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.1% |
|---|---|
| 1 month | +7.0% |
| 3 months | +13.1% |
| 6 months | +107.1% |
| 1 year | +90.5% |
| 3 years | +117.9% |
| 5 years | +33.4% |
Signals
| 50-day / 200-day average | 69.39 / 46.88 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.80 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Mar 2026 | EUR 1.2000 |
| 19 Mar 2025 | EUR 1.6000 |
| 15 Mar 2024 | EUR 1.4500 |
| 17 Mar 2023 | EUR 1.4500 |
| 17 Mar 2022 | EUR 1.4500 |
| 12 Mar 2021 | EUR 1.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.